TY  - JOUR
AU  - Maksimović-Ivanić, Danijela
AU  - Fagone, Paolo
AU  - McCubrey, James
AU  - Bendtzen, Klaus
AU  - Mijatović, Sanja
AU  - Nicoletti, Ferdinando
PY  - 2017
UR  - http://doi.wiley.com/10.1002/ijc.30529
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2553
AB  - The possible use of HIV protease inhibitors (HIV-PI) as new therapeutic option for the treatment of cancer primarily originated from their success in treating HIV-related Kaposi's sarcoma (KS). While these findings were initially attributed to immune reconstitution and better control of oncogenic viral infections, the number of reports on solid tumors, KS, lymphoma, fibrosarcoma, multiple myeloma and prostate cancer suggest other mechanisms for the anti-neoplastic activity of PIs. However, a major drawback for the possible adoption of HIV-PIs in the therapy of cancer relies on their relatively weak anticancer potency and important side effects. This has propelled several groups to generate derivatives of HIV-PIs for anticancer use, through modifications such as attachment of different moieties, ligands and transporters, including saquinavir-loaded folic acid conjugated nanoparticles and nitric oxide (NO) derivatives of HIV-PIs. In this article, we discuss the current preclinical and clinical evidences for the potential use of HIV-PIs, and of novel derivatives, such as saquinavir-NO in the treatment of cancer.
T2  - International Journal of Cancer
T1  - HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?
DO  - 10.1002/ijc.30529
ER  - 

@article{
author = "Maksimović-Ivanić, Danijela and Fagone, Paolo and McCubrey, James and Bendtzen, Klaus and Mijatović, Sanja and Nicoletti, Ferdinando",
year = "2017",
abstract = "The possible use of HIV protease inhibitors (HIV-PI) as new therapeutic option for the treatment of cancer primarily originated from their success in treating HIV-related Kaposi's sarcoma (KS). While these findings were initially attributed to immune reconstitution and better control of oncogenic viral infections, the number of reports on solid tumors, KS, lymphoma, fibrosarcoma, multiple myeloma and prostate cancer suggest other mechanisms for the anti-neoplastic activity of PIs. However, a major drawback for the possible adoption of HIV-PIs in the therapy of cancer relies on their relatively weak anticancer potency and important side effects. This has propelled several groups to generate derivatives of HIV-PIs for anticancer use, through modifications such as attachment of different moieties, ligands and transporters, including saquinavir-loaded folic acid conjugated nanoparticles and nitric oxide (NO) derivatives of HIV-PIs. In this article, we discuss the current preclinical and clinical evidences for the potential use of HIV-PIs, and of novel derivatives, such as saquinavir-NO in the treatment of cancer.",
journal = "International Journal of Cancer",
title = "HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?",
doi = "10.1002/ijc.30529"
}

Maksimović-Ivanić, D., Fagone, P., McCubrey, J., Bendtzen, K., Mijatović, S.,& Nicoletti, F.. (2017). HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. in International Journal of Cancer.
https://doi.org/10.1002/ijc.30529

Maksimović-Ivanić D, Fagone P, McCubrey J, Bendtzen K, Mijatović S, Nicoletti F. HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?. in International Journal of Cancer. 2017;.
doi:10.1002/ijc.30529 .

Maksimović-Ivanić, Danijela, Fagone, Paolo, McCubrey, James, Bendtzen, Klaus, Mijatović, Sanja, Nicoletti, Ferdinando, "HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?" in International Journal of Cancer (2017),
https://doi.org/10.1002/ijc.30529 . .

TY  - JOUR
AU  - Maksimović-Ivanić, Danijela
AU  - Mojić, Marija
AU  - Bulatović, Mirna Z.
AU  - Radojkovic, Milica
AU  - Kuzmanovic, Milos
AU  - Ristic, Slobodan
AU  - Stošić-Grujičić, Stanislava
AU  - Miljković, Đorđe
AU  - Cavalli, Eugenio
AU  - Libra, Massimo
AU  - Fagone, Paolo
AU  - McCubrey, James
AU  - Nicoletti, Ferdinando
AU  - Mijatović, Sanja
PY  - 2015
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2353
AB  - Covalent attachment of NO to the first approved HIV protease inhibitor
   Saquinavir (Saq-NO) expands the therapeutic potential of the original
   drug. Apart from retained antiviral activity, the modified drug exerts
   strong antitumor effects and lower toxicity. In the present study, we
   have evaluated the sensitivity of different hematological malignancies
   to Saq-NO. Saq-NO efficiently diminished the viability of Jurkat, Raji,
   HL-60 and K562 cells. While Jurkat and Raji cells (established from
   pediatric patients) displayed abrogated proliferative potential, HL-60
   and K652 cells (originated from adults) exposed to Saq-NO treatment
   underwent caspase dependent apoptosis. In addition, similar sensitivity
   to Saq-NO was observed in mononuclear blood cells obtained from
   pediatric patients with acute lymphoblastic leukemia (ALL) and adult
   patients with acute myeloid leukemia (AML). Western blot analysis
   indicated p70S6 kinase as a possible intracellular target of Saq-NO
   action. Moreover, the addition of a NO moiety to Lopinavir resulted in
   improved antitumor potential as compared to the parental compound,
   suggesting that NO-derived HIV protease inhibitors are a potential new
   source of anticancer drugs with unique mode of action. (C) 2015 Elsevier
   Ltd. All rights reserved.
T2  - Leukemia Research
T1  - The NO-modified HIV protease inhibitor as a valuable drug for
 hematological malignancies: Role of p70S6K
IS  - 10
VL  - 39
DO  - 10.1016/j.leukres.2015.06.013
SP  - 1088
EP  - 1095
ER  - 

@article{
author = "Maksimović-Ivanić, Danijela and Mojić, Marija and Bulatović, Mirna Z. and Radojkovic, Milica and Kuzmanovic, Milos and Ristic, Slobodan and Stošić-Grujičić, Stanislava and Miljković, Đorđe and Cavalli, Eugenio and Libra, Massimo and Fagone, Paolo and McCubrey, James and Nicoletti, Ferdinando and Mijatović, Sanja",
year = "2015",
abstract = "Covalent attachment of NO to the first approved HIV protease inhibitor
   Saquinavir (Saq-NO) expands the therapeutic potential of the original
   drug. Apart from retained antiviral activity, the modified drug exerts
   strong antitumor effects and lower toxicity. In the present study, we
   have evaluated the sensitivity of different hematological malignancies
   to Saq-NO. Saq-NO efficiently diminished the viability of Jurkat, Raji,
   HL-60 and K562 cells. While Jurkat and Raji cells (established from
   pediatric patients) displayed abrogated proliferative potential, HL-60
   and K652 cells (originated from adults) exposed to Saq-NO treatment
   underwent caspase dependent apoptosis. In addition, similar sensitivity
   to Saq-NO was observed in mononuclear blood cells obtained from
   pediatric patients with acute lymphoblastic leukemia (ALL) and adult
   patients with acute myeloid leukemia (AML). Western blot analysis
   indicated p70S6 kinase as a possible intracellular target of Saq-NO
   action. Moreover, the addition of a NO moiety to Lopinavir resulted in
   improved antitumor potential as compared to the parental compound,
   suggesting that NO-derived HIV protease inhibitors are a potential new
   source of anticancer drugs with unique mode of action. (C) 2015 Elsevier
   Ltd. All rights reserved.",
journal = "Leukemia Research",
title = "The NO-modified HIV protease inhibitor as a valuable drug for
 hematological malignancies: Role of p70S6K",
number = "10",
volume = "39",
doi = "10.1016/j.leukres.2015.06.013",
pages = "1088-1095"
}

Maksimović-Ivanić, D., Mojić, M., Bulatović, M. Z., Radojkovic, M., Kuzmanovic, M., Ristic, S., Stošić-Grujičić, S., Miljković, Đ., Cavalli, E., Libra, M., Fagone, P., McCubrey, J., Nicoletti, F.,& Mijatović, S.. (2015). The NO-modified HIV protease inhibitor as a valuable drug for
 hematological malignancies: Role of p70S6K. in Leukemia Research, 39(10), 1088-1095.
https://doi.org/10.1016/j.leukres.2015.06.013

Maksimović-Ivanić D, Mojić M, Bulatović MZ, Radojkovic M, Kuzmanovic M, Ristic S, Stošić-Grujičić S, Miljković Đ, Cavalli E, Libra M, Fagone P, McCubrey J, Nicoletti F, Mijatović S. The NO-modified HIV protease inhibitor as a valuable drug for
 hematological malignancies: Role of p70S6K. in Leukemia Research. 2015;39(10):1088-1095.
doi:10.1016/j.leukres.2015.06.013 .

Maksimović-Ivanić, Danijela, Mojić, Marija, Bulatović, Mirna Z., Radojkovic, Milica, Kuzmanovic, Milos, Ristic, Slobodan, Stošić-Grujičić, Stanislava, Miljković, Đorđe, Cavalli, Eugenio, Libra, Massimo, Fagone, Paolo, McCubrey, James, Nicoletti, Ferdinando, Mijatović, Sanja, "The NO-modified HIV protease inhibitor as a valuable drug for
 hematological malignancies: Role of p70S6K" in Leukemia Research, 39, no. 10 (2015):1088-1095,
https://doi.org/10.1016/j.leukres.2015.06.013 . .